Ancestry.Com Moves Further Into Consumer Genetics With Launch of AncestryHealth

Genetics Investing

The MIT Technology Review reports that Ancestry.Com’s (NASDAQ:ACOM) launch of AncestryHealth will further position the company as a player in the consumer genetics market.

The MIT Technology Review reports that Ancestry.Com’s (NASDAQ:ACOM) launch of AncestryHealth will further position the company as a player in the consumer genetics market.
According to the article:

With the Thursday launch of its AncestryHealth website, Ancestry continues to play Microsoft to 23andMe’s Apple. It may not be as innovative in the burgeoning field of consumer genetics, but it’s an able competitor nonetheless.
Ancestry entered the field of consumer DNA analysis in 2012 with the launch of AncestryDNA, a $99 spit test that will analyze your DNA for details about your ethnic makeup and connect you with distant relatives. This was five years after 23andMe began to offer similar DNA-testing kits.
[…] The FDA cracked the door in February to allow 23andMe to market a direct-to-consumer genetic test for Bloom syndrome, and it seems likely that both Ancestry and 23andMe may try to move in the direction of tailoring their tests to specific diseases, depending on the FDA’s signals.

Click here to read the full article on MIT Technology Review.
 

 

The Conversation (0)
×